EOLS Q1 2023 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$42M+23.0% YoY

Gross Profit

$30M70.9% margin

Operating Income

-$12M-28.9% margin

Net Income

-$15M-35.5% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-4.4%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$160M

Total Liabilities

$153M

Stockholders' Equity

$7M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$34M	+23.0%
Gross Profit	$30M	$21M	+42.9%
Operating Income	-$12M	-$15M	+22.1%
Net Income	-$15M	-$18M	+15.5%

Revenue Segments

Product

$41M98%

Service

$674,0002%